Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Lesion Management Applications Developed for Chest and Abdominal CT Scans.

By HospiMedica staff writers
Posted on 13 Nov 2007
Lesion management solutions (LMS) are a range of clinical applications for the management of cancerous or other suspicious lesions diagnosed in chest and abdominal computed tomography (CT) scans.

The Median LMS-Lung, LMS-Liver and LMS-Colon applications, developed by Median Technologies (Biot, France), were introduced one year ago and have already been deployed in 20 European sites including 12 in France, and their integration has been validated with major picture archiving and communication systems (PACS) and radiology information systems (RIS). More...


The LMS-Lung is intended to help the radiologists detect, quantify, and follow pulmonary nodules, and the LMS-Liver to facilitate the initial evaluation and the follow-up of liver lesions. Both applications also generate reports according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria used to evaluate the response to treatment of solid tumors. LMS-Colon provides clinicians with advanced functionalities to help them detect and quantify polyps.

"All LMS applications are designed to be integrated in clinical routine and contribute to improve the workflow and productivity,” says Gerard Milhiet, COO of Median Technologies. "This improvement is achieved by automating all the tedious tasks the radiologists would normally carry out manually, and by integrating the applications with PACS or RIS workstations.”

This integration provides access to previous exams necessary to perform follow-up studies, brings additional clinical functionalities to the radiologists' desktop wherever needed in the hospital, and ensures an immediate report transmission to the referring physicians.

Fredrik Brag, CEO of Median Technologies commented, when asked about the company's future plans, "we have chosen the road of CT oncology which mainly consists in evaluating and following cancerous or other suspicious lesions. We already offer a comprehensive portfolio of applications in this field and aim at extending it.”

Median Technologies develops and commercializes advanced clinical applications for diagnostic oncology imaging.


Related Links:
Median Technologies

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.